Encoded Therapeutics Raises $275 Million in Series F Financing to Advance ETX101 Through Pivotal Development and Accelerate its Precision Genetic Medicines Neurology Pipeline

Encoded Therapeutics raised $275 million in a Series F financing to advance its precision genetic medicines pipeline for neurological diseases. The sizable private funding round strengthens the biotech's capacity to fund clinical development, though the release provides no further terms, valuation, or program-specific milestones.